11/08/2017 Physiogenex to present its NASH models at EASL NAFLD Summit 2017
Physiogenex will present at the EASL NAFLD Summit in Rome, Italy, November 9th-11th, 2017.
Dr. François Briand, Director of Research and Business Development, will be presenting an e-poster about the effects of obeticholic acid in various Physiogenex preclinical NASH models, during the e-poster session 3, Nov. the 9th, 08:00pm-08:20pm.
If you wish to further discuss about our NASH models to optimize your preclinical drug development program,
please contact us to set-up an appointment with Dr. François Briand during the EASL NAFLD summit.
We look forward seeing you in Rome, Italy!
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.
Please visit our website for more information